Kidney Disease Clinical Trials: Recruiting Studies
Recruiting kidney disease clinical trials, listed from live ClinicalTrials.gov records with each trial's official title, phase, conditions, locations and a direct link to its full record.
These listings cover recruiting studies in kidney disease — including chronic kidney disease and kidney cancer research — exactly as the ClinicalTrials.gov records describe them. A listing here is not a recommendation: whether a trial could be relevant depends on your diagnosis, stage, treatment history and the trial's own eligibility criteria, which only the trial team can assess.
Trial data from ClinicalTrials.gov, fetched November 17, 2026 — always confirm details on the trial's own page.
Recruiting trials, most recently updated first
Showing the 20 most recently updated recruiting trials from a search that matched 1,864 records in total on the fetch date. The full, live list is on ClinicalTrials.gov.
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.
1 study locations, none listed in the United States (including Nanjing, Jiangsu).
Application Research of Hydromorphinone Sustained-release Tablets in the Treatment of Elderly Patients With Cancer Pain Accompanied by Renal Insufficiency
This clinical study aims to understand whether domestic hydromorphinone sustained-release tablets are effective and safe in treating moderate to severe cancer pain in elderly patients with renal insufficiency. It will also understand key safety concerns, especially regarding renal function and neurotoxicity. The main…
1 study locations, none listed in the United States (including Tai’an, Shandong).
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given…
8 study locations, 8 in the United States (including Los Angeles, California; Orange, California; Miami, Florida).
Clinical Experience With Iptacopan in Adult Patients With Complement 3 Glomerulopathy (C3G): A Multicenter, Observational, Retrospective Study of Patients Treated Through an Early Access Program in Spain
This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.
5 study locations, none listed in the United States (including Las Palmas de Gran C, Las Palmas; Valencia, Valencia; Córdoba, Spain).
An Open-Label, Adaptive Single-Dose Trial to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Afabicin
The primary purpose of this study is to assess the effect of renal impairment on the PK of afabicin desphosphono after a single oral 80 milligrams (mg) or intravenous (IV) 55 mg dose of afabicin.
1 study locations, none listed in the United States (including Berlin, Germany).
Hematological Alterations Associated With the Use of Dipyrone Versus Paracetamol After Dental Extractions: a Double-blind, Randomized Clinical Trial
The goal of this clinical trial is to compare the safety of dipyrone and paracetamol when used for pain relief after dental extractions in adults. The study will focus on changes in blood cell counts and will also evaluate liver and kidney function and possible side effects. The main questions it aims to answer are: *…
1 study locations, none listed in the United States (including Juiz de Fora, Minas Gerais).
A Phase 3b, Open-label, Single-arm, Patient Experience Study of Povetacicept Injection (Via Autoinjector) as Compared to Sibeprenlimab Injection (Via Prefilled Syringe) in Adults With Immunoglobulin A Nephropathy
The purpose of this study is to evaluate participant treatment experience with Povetacicept injection administered via autoinjector relative to Sibeprenlimab injection administered via prefilled syringe (PFS), and to assess the safety and tolerability of Povetacicept in participants with Immunoglobulin A nephropathy…
1 study locations, 1 in the United States (including Orlando, Florida).
Carvedilol + Simvastatin vs. Carvedilol Alone for Chronic Liver Disease and Cirrhotic Cardiomyopathy and Its Impact on Hepatic Decompensation and Survival; a Double-blind Randomized Controlled Trial
Cirrhosis and portal hypertension are associated with a hyperdynamic circulation and decompensation events, including development of ascites, variceal bleeding, acute kidney injury, and susceptibility to infections. Rationale: Cirrhosis and portal hypertension are associated with a hyperdynamic circulation and…
1 study locations, none listed in the United States (including Chandigarh, India).
A Phase 1a/1b, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109, When Administered Alone for the Treatment of Advanced or Metastatic Solid Tumors, and in Combination With Atezolizumab for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preliminary efficacy, pharmacokinetics, immunogenicity, pharmacodynamics of LB-LR1109…
1 study locations, 1 in the United States (including Fairfax, Virginia).
Histotripsy for Renal Cell Carcinoma: a Pilot Study for a Novel Focused Therapy With an Unmet Need
The project will be a pilot study in localised or metastatic renal cell carcinoma, assessing safety, local control, and exploratory immune endpoints. Outcomes from this work will inform rational combinations with targeted agents and immune checkpoint blockade and may define a new, image-guided, non-invasive modality…
1 study locations, none listed in the United States (including Hong Kong, Hong Kong).
Cobas® Lumira Collection of Venous and Capillary Blood Samples for the Research, Optimization and Calibration of New Diagnostic Devices (EVOLVE)
This study is a blood sample collection study, collecting venous and capillary blood samples from adult patients in the UK, with a range of health conditions. The purpose of this study is to collect blood samples to help develop, improve, and fine-tune new and existing diagnostic tests for the cobas® lumira…
1 study locations, none listed in the United States (including Glasgow, United Kingdom).
A Phase II Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Mosunetuzumab in Patients With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
This study will assess how mosunetuzumab works in people who have systemic lupus erythematosus (SLE) who may or may not also have active lupus nephritis (LN).
24 study locations, none listed in the United States (including CABA, Buenos Aires; Buenos Aires, Ciudad Autonoma Buenos Aires; Salvador, Estado de Bahia).
An Observational Study of the Efficacy and Safety of Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and…
1 study locations, none listed in the United States (including Nanjing, Jiangsu).
A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or Arm C (standard ipilimumab/ nivolumab), respectively.
6 study locations, 6 in the United States (including Washington D.C., District of Columbia; Chapel Hill, North Carolina; Cleveland, Ohio).
A Randomized Phase II Trial Comparing Daratumumab-Bortezomib-Dexamethasone Versus Cyclophosphamide-Bortezomib-Dexamethasone in Newly Diagnosed Multiple Myeloma With Light Chain Cast Nephropathy (LCCN)
This study is being done to answer the following question: Can the addition of daratumumab-hyaluronidase to the usual treatment of bortezomib and dexamethasone improve kidney function in patients who are newly diagnosed with multiple myeloma and have kidney failure? This study is being done because the investigators…
1 study locations, 1 in the United States (including Anchorage, Alaska).
An Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Multimodal Radiotherapy in the Treatment of Renal Cell Carcinoma Progressed After Prior Immunotherapy
The objective of this single-center clinical study was to evaluate the disease control rate(DCR) and safety of multimodal radiotherapy in the treatment of patients with renal cell carcinoma (RCC) progressed after prior immunotherapy.
1 study locations, none listed in the United States (including Nanjing, Jiangsu).
An Open-label, Multicenter, Phase 2 Study of First-line Lenvatinib Plus Pembrolizumab and Later-line Lenvatinib Plus Everolimus in Patients With Metastatic Chromophobe Renal Cell Carcinoma.
Chromophobe renal cell carcinoma (chRCC) accounts for approximately 5% of RCC cases and has distinct morphological and molecular features. However, advanced chRCC follows an aggressive clinical course and responds poorly to standard regimens developed for clear cell RCC. Lenvatinib plus everolimus (LEN+EVE) has…
8 study locations, none listed in the United States (including Chelyabinsk, Russia; Krasnoyarsk, Russia; Orenburg, Russia).
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Trial Participants With Varying Degrees of Renal Impairment and in Those With Normal Renal Function
This Phase 1 study is designed to evaluate the pharmacokinetics and safety of a single oral dose of DA-302168S in subjects with moderate renal impairment (with the possible inclusion of subjects with mild renal impairment), compared with age-, sex-, and body mass index (BMI)-matched subjects with normal renal…
1 study locations, none listed in the United States (including Suzhou, Jiangsu).
Implementing Precision Medicine for Glomerular Diseases in the Nephrotic Syndrome Study Network (NEPTUNE)
NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.
16 study locations, 16 in the United States (including Atlanta, Georgia; Chicago, Illinois; Kansas City, Kansas).
The Effects of Increased Water Intake on Muscle Function, Physical Performance, and Endocrine Regulation in Low-Drinking Older Adults: A Randomized Controlled Trial
Population aging represents one of the major demographic transformations of the 21st century. However, increased longevity has not been accompanied by preserved functional independence. Falls are currently the leading cause of injury-related mortality and a major contributor to hospitalization, disability, and…
1 study locations, none listed in the United States (including Rio Maior, Portugal).
More from the Clinical Trials Finder
This page is general information only. It is not medical advice, it does not say whether any trial is right for you, and it makes no promise about eligibility or enrollment. Clinical trials have eligibility criteria set by the trial team, and taking part is always voluntary. Talk to your own care team before contacting any trial, and confirm every detail on the trial's own ClinicalTrials.gov page.